| Literature DB >> 33668340 |
Jun-Jie Shi1, Qi-Hui Jiang2, Tian-Ning Zhang2, Hao Sun1, Wen-Wen Shi1, Hendra Gunosewoyo3, Fan Yang1, Jie Tang4, Tao Pang2, Li-Fang Yu1.
Abstract
Sigma-1 (σ-1) receptor agonists are considered as potential treatment for stroke. TS-157 is an alkoxyisoxazole-based σ-1 receptor agonist previously discovered in our group. The present study describes TS-157 profile in a battery of tests for cerebral ischemia. Initial evaluation demonstrated the compound's safety profile and blood-brain barrier permeability, as well as its ability to induce neurite outgrowth in vitro. The neurite outgrowth was shown to be mediated via σ-1 receptor agonism and involves upregulation of ERK phosphorylation (pERK). In particular, TS-157 also significantly accelerated the recovery of motor function in rats with transient middle cerebral artery occlusion (tMCAO). Overall, the results herein support the notion that σ-1 receptor agonists are potential therapeutics for stroke and further animal efficacy studies are warranted.Entities:
Keywords: TS-157; focal cerebral ischemia; neurite outgrowth; pERK; sigma-1 receptor
Mesh:
Substances:
Year: 2021 PMID: 33668340 PMCID: PMC7956808 DOI: 10.3390/molecules26051212
Source DB: PubMed Journal: Molecules ISSN: 1420-3049 Impact factor: 4.411